QTTB — Q32 Bio Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1661998 ·
Last close
$8.63
Market Cap
$258.24M
52W High
$23.57
52W Low
$1.90
ADV30
477,137
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -10,660,000 -8,922,000 297,201,000 289,587,000 9,531,000
Jun 2026 0 — -9,118,000 -8,946,000 115,867,000 106,270,000 9,962,000
Mar 2026 0 — -7,722,000 -7,609,000 63,675,000 50,751,000 17,362,000
Dec 2025 53,737,000 — 45,879,000 57,730,000 61,776,000 48,297,000 19,762,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-20,016,000
Investing CF
$7,000,000
Financing CF
$253,616,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.84
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-230,470,000
Inventory
—
Receivables
$555,000
ST Investments
—
EBIT TTM
$30,430,000
Pretax Income TTM
$32,253,000
Interest Exp TTM
$1,100,000
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$53,737,000
EBITDA
$18,728,000
Free Cash Flow
$14,419,875
Enterprise Value
$-8,427,092
Total Cash
$289,587,008
Total Debt
$4,364,000
Shares Out
29,923,882
Trailing EPS
$3.60
Book Value
$9.62
ROE
24.0%
ROA
6.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 53,737,000 16,902,000 29,821,000 61,776,000 19,762,000 42,014,000 -33,543,000
Dec 2024 0 -66,102,000 -47,733,000 92,332,000 86,657,000 5,675,000 -67,715,000
Dec 2023 -6,651,000 -48,255,000 -53,743,000 47,057,000 229,978,000 -182,921,000 -18,677,000
Dec 2022 6,651,000 -39,225,000 -42,809,000 61,774,000 192,486,000 -130,712,000 -10,957,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$53,737,000
NetIncome TTM
$33,786,000
OpCashFlow TTM
—
Assets (Latest)
$115,867,000
Forward EPS
$-1.02

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $15.00 · spot: $8.53 · call volume: 27 · put volume: 234

Peers — same industry

TickerNameMarket CapLastDaily %
TTRX Turn Therapeutics Inc. $261.40M $8.55 —
ENTA ENANTA PHARMACEUTICALS INC $253.10M $8.69 —
CAMP Camp4 Therapeutics Corp $251.02M $4.00 —
NWBO NORTHWEST BIOTHERAPEUTICS INC $250.73M $0.15 —
PRE Prenetics Global Ltd $248.19M $16.33 —

News headlines (Yahoo Finance, 1h cache)

Q32 Bio to Participate in the 2026 Jefferies Global Healthcare Conference in London
2026-11-11 11:59 · Yahoo
Q32 Bio: Q3 Earnings Snapshot
2026-11-04 12:11 · Yahoo
Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-04 11:59 · Yahoo
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026
2026-09-30 13:15 · Yahoo
Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Co
2026-09-21 13:15 · Yahoo
Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer
2026-09-14 10:59 · Yahoo
Down 23.1% in 4 Weeks, Here's Why Q32 Bio (QTTB) Looks Ripe for a Turnaround
2026-09-07 13:35 · Yahoo
Q32 Bio to Participate in Upcoming September Investor Conferences
2026-09-01 10:59 · Yahoo
Wall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?
2026-08-17 13:55 · Yahoo
Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice
2026-07-20 16:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.